Paper322648
Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma.
Zimmerman TJ and 1 other. Arch Ophthalmol, 1977. Cited by 387 papers, by iCite.
Cite this record
ConductScience Library. Timolol. A beta-adrenergic blocking agent for the treatment of glaucoma. Papers, record 322648. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/322648
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Glaucoma | Major topic |
| Propanolamines | Major topic |
| Timolol | Major topic |
| Clinical Trials as Topic | |
| Humans | |
| Intraocular Pressure | |
| Ophthalmic Solutions | |
| Placebos | |
| Reflex, Pupillary | |
| Visual Acuity |
Source PubMed
Cited by93
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 387 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41665855 | Computational study of Durysta® implant for glaucoma treatment: drug dispersion and aqueous humor flow in the anterior chamber. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/41665855 | PubMed |
| 41563533 | Adverse effects of antiglaucoma medications: pathophysiology and novel drug delivery strategies for mitigation. | Int Ophthalmol | 2026 | https://conductscience.org/library/papers/41563533 | PubMed |
| 41471311 | Challenge of Corneal Ulcer Healing: A Novel Conceptual Framework, the "Triad" of Corneal Ulcer Healing/Corneal Neovascularization/Intraocular Pressure, and Avascular Tendon Healing, for Evaluation of Corneal Ulcer Therapy, Therapy of Neovascularization, Glaucoma Therapy, and Pentadecapeptide BPC 157 Efficacy. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41471311 | PubMed |
| 39697579 | Timolol 0.5% Eye Drops for Essential Tremor: First Successful Case Report. | Mo Med | 2024 | https://conductscience.org/library/papers/39697579 | PubMed |
| 38493240 | SpaceGrow: efficient shape-based virtual screening of billion-sized combinatorial fragment spaces. | J Comput Aided Mol Des | 2024 | https://conductscience.org/library/papers/38493240 | PubMed |
| 38399328 | Chemical Insights into Topical Agents in Intraocular Pressure Management: From Glaucoma Etiopathology to Therapeutic Approaches. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38399328 | PubMed |
| 38082203 | Adrenoceptors in the Eye - Physiological and Pathophysiological Relevance. | Handb Exp Pharmacol | 2024 | https://conductscience.org/library/papers/38082203 | PubMed |
| 37695021 | The Photochemical Mediated Ring Contraction of 4H-1,2,6-Thiadiazines To Afford 1,2,5-Thiadiazol-3(2H)-one 1-Oxides. | Org Lett | 2023 | https://conductscience.org/library/papers/37695021 | PubMed |
| 34427248 | Incidence of presumed steroid response in contralateral eye of patients who underwent glaucoma filtration surgery. | Indian J Ophthalmol | 2021 | https://conductscience.org/library/papers/34427248 | PubMed |
| 33963917 | Inter-eye relationship of intraocular pressure change after unilateral trabeculectomy, filtering canaloplasty, or PreserFlo™ microshunt implantation. | Graefes Arch Clin Exp Ophthalmol | 2021 | https://conductscience.org/library/papers/33963917 | PubMed |
| 33201931 | Intraocular pressure change with face-down positioning after macular hole surgery. | PLoS One | 2020 | https://conductscience.org/library/papers/33201931 | PubMed |
| 33108623 | Dorzolamide/Timolol Fixed Combination: Learning from the Past and Looking Toward the Future. | Adv Ther | 2021 | https://conductscience.org/library/papers/33108623 | PubMed |
| 32940661 | Physiologic Consequences of Caveolin-1 Ablation in Conventional Outflow Endothelia. | Invest Ophthalmol Vis Sci | 2020 | https://conductscience.org/library/papers/32940661 | PubMed |
| 31637100 | Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds. | Adv Wound Care (New Rochelle) | 2019 | https://conductscience.org/library/papers/31637100 | PubMed |
| 31057923 | Towards smart self-clearing glaucoma drainage device. | Microsyst Nanoeng | 2018 | https://conductscience.org/library/papers/31057923 | PubMed |
| 31010869 | Natamycin and Voriconazole Exhibit Synergistic Interactions with Nonantifungal Ophthalmic Agents against Fusarium Species Ocular Isolates. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/31010869 | PubMed |
| 30794789 | Effect of Timolol on Aqueous Humor Outflow Facility in Healthy Human Eyes. | Am J Ophthalmol | 2019 | https://conductscience.org/library/papers/30794789 | PubMed |
| 29966397 | Therapeutic Contact Lenses with Polymeric Vehicles for Ocular Drug Delivery: A Review. | Materials (Basel) | 2018 | https://conductscience.org/library/papers/29966397 | PubMed |
| 29767982 | DenTimol as A Dendrimeric Timolol Analogue for Glaucoma Therapy: Synthesis and Preliminary Efficacy and Safety Assessment. | Mol Pharm | 2018 | https://conductscience.org/library/papers/29767982 | PubMed |
| 28480761 | Topical treatment of glaucoma: established and emerging pharmacology. | Expert Opin Pharmacother | 2017 | https://conductscience.org/library/papers/28480761 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/322648
GET https://conductscience.org/api/papers/v1/322648/cited_by?page=2